Observational studyActa neurochirurgica2025
Accuracy of frameless stereotactic brain biopsy: a retrospective cohort study with MRI-only and MRI-CT fusion navigation.
Observational study in Acta neurochirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparison of the Diagnostic Efficacy of Frameless Stereotactic Biopsy (Varioguide) with Other Methods Reported in the Literature: A Single-Center Experience.Journal of clinical practice and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStereotactic-guided biopsy remains the gold standard for diagnosing intracranial lesions not amenable to surgical resection. Frameless techniques, such as the VarioGuide® system (Brainlab AG, Munich, Germany), offer a minimally invasive alternative, typically using MRI-based navigation. However, MRI-based navigation may be affected by geometric distortions that impair targeting precision. CT imaging provides superior geometric fidelity. This retrospective analysis evaluates the accuracy of frameless stereotactic biopsies in clinical routine. Patients were grouped based on the imaging modality used for neuronavigation-either MRI-only or MRI-CT fusion-allowing secondary comparison between both approaches.
methodsIn this retrospective cohort study, 99 patients who underwent frameless stereotactic biopsy between February 2022 and September 2024 were analysed. Patients were grouped by neuronavigation modality: CT-MRI fusion-based (n = 18) and MRI-only (n = 81). Accuracy was assessed by measuring entry and target deviations using postoperative CT. Lesion volume, depth, procedure duration, and complication rates were also evaluated.
resultsEntry and targeting accuracy was comparable between groups (entry deviation: 5.2 ± 3.9 mm vs. 5.4 ± 3.0 mm, p = 0.84; target deviation: 4.2 ± 3.0 mm vs. 4.4 ± 2.7 mm, p = 0.85). Lesion volume and target depth showed no significant differences. No statistically significant differences in complication rates were observed between groups (27.8% vs. 11.1%, p = 0.14).
conclusionMRI-only and CT-MRI fusion-based frameless stereotactic biopsies showed no statistically significant difference in targeting accuracy. While CT-based registration may theoretically reduce distortion-related errors, this was not reflected in our data. The choice of imaging modality should therefore be guided by clinical context and imaging availability. Further prospective studies are needed to clarify the value of CT integration in specific clinical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.